Comparative Pharmacology
Head-to-head clinical analysis: ASPARLAS versus VITRASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPARLAS versus VITRASE.
ASPARLAS vs VITRASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asparaginase (ASPARLAS) hydrolyzes L-asparagine to L-aspartic acid and ammonia, depleting circulating asparagine. Leukemic cells with low asparagine synthetase activity rely on exogenous asparagine; depletion inhibits protein and nucleic acid synthesis, leading to cell death.
VITRASE (hyaluronidase) hydrolyzes hyaluronic acid, a component of the extracellular matrix, thereby increasing tissue permeability to fluids and facilitating the absorption and dispersion of injected drugs.
Intravenous (IV) or intramuscular (IM) injection: 2,500 IU/m² every 14 days as a component of multi-agent chemotherapy. Administer IV over 1-2 hours in 100 mL of 0.9% sodium chloride.
Intravenous administration of 150 units as a bolus injection prior to subcutaneous fluid or medication administration to increase absorption and dispersion.
None Documented
None Documented
The terminal elimination half-life is approximately 25.7 days (range 17.8–33.6 days) in children and 22.0 days in adults, allowing for dosing every 2 weeks instead of 3 times per week as with native E. coli asparaginase.
Approximately 24 hours for the enzymatic activity; clinical effect persists beyond half-life due to drug action.
Calaspargase pegol (ASPARLAS) is eliminated via the reticuloendothelial system; renal excretion is negligible (<2% unchanged), and biliary/fecal excretion has not been quantified. The pegylated asparaginase is cleared through proteolytic degradation.
Renal: <10% unchanged; remainder metabolized locally.
Category C
Category C
Antineoplastic, Enzyme
Enzyme